French drugmaker Sanofi posted stronger third-quarter profit growth than analysts expected, helped by an earlier-than-expected start to the vaccination season. The company’s quarterly operating income, excluding non-recurring items, rose 14.4% to 4.6 billion euros ($5.0 billion), beating analysts’ average estimate of 4 billion euros in a survey on the company’s website.